Table 2 Currently available drug regimens for the treatment of latent tuberculosis infection
From: New approaches in the diagnosis and treatment of latent tuberculosis infection
Drug(s) | Adult maximum dose(s) (mg) | Duration of treatment | Drug intake | Frequency | Comments |
|---|---|---|---|---|---|
INH | 300 | 9 months | Self administered | Daily | Preferred regimen by CDC |
INH | 900 | 9 months | Under DOT | 2/Wk | Alternative regimen |
INH | 300 | 6 months | Self administered | Daily | For HIV seronegative only |
INH | 900 | 6 months | Under DOT | 2/Wk | For HIV seronegative only |
INH | 300 | 12 months | Self administered | Daily | Preferred regimen by IUAT |
RMP | 600 | 4 months | Self administered | Daily | For LTBI with INHr strain in HIV seronegative subjects |
INH + RMP | 300 + 600 | 3 months | Self administered | Daily | Good alternative option |
RMP + PZA | 600 + 2000 | 2 months | Self administered | Daily | Higher risk of hepatotoxicity |
RMP + PZA | 600 + 2500 | 2 months | Under DOT | 2/Wk | Higerh risk of hepatotoxicity |
INH + RPE | 900 + 900 | 3 months | Under DOT | 1/Wk | Promising option |